Better end points needed in primary sclerosing cholangitis trials
A new study of a fibroblast growth factor 19 analogue in patients with primary sclerosing cholangitis (PSC) provides provocative results. The data challenge alkaline phosphatase levels as the appropriate surrogate end point in PSC trials and highlight alternatives, urging efforts to identify better...
Gespeichert in:
| Veröffentlicht in: | Nature reviews. Gastroenterology & hepatology 2019-03, Vol.16 (3), p.143-144 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | A new study of a fibroblast growth factor 19 analogue in patients with primary sclerosing cholangitis (PSC) provides provocative results. The data challenge alkaline phosphatase levels as the appropriate surrogate end point in PSC trials and highlight alternatives, urging efforts to identify better clinical end points for this disease. |
|---|---|
| ISSN: | 1759-5045 1759-5053 |
| DOI: | 10.1038/s41575-019-0110-5 |